CD19 and myasthenia gravis: In parallel, there are two more phase 1 clinical trials (NCT04561557, NCT06680037) of CAR T-cells targeting BCMA and CD19, respectively, in patients with B-cell/Antibody-driven autoimmune disorders, including all the above-mentioned ones (MS, MG, NMOSD, MOGAD, AE, SPS, CIPD) (84, 85).